Compare FLYX & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FLYX | VANI |
|---|---|---|
| Founded | 2015 | 1998 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.7M | 95.8M |
| IPO Year | N/A | N/A |
| Metric | FLYX | VANI |
|---|---|---|
| Price | $2.36 | $1.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 203.4K | ★ 563.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.72 | N/A |
| Revenue Next Year | $8.54 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.90 | $0.91 |
| 52 Week High | $8.88 | $1.92 |
| Indicator | FLYX | VANI |
|---|---|---|
| Relative Strength Index (RSI) | 39.03 | 46.23 |
| Support Level | $2.56 | $1.16 |
| Resistance Level | $3.31 | $1.31 |
| Average True Range (ATR) | 0.32 | 0.09 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 4.63 | 27.27 |
flyExclusive Inc is an owner and operator of curated private aviation experiences dedicated to surpassing passenger expectations for quality, convenience, and safety. Its mission is to be the world's majority vertically integrated private aviation company through capital-efficient program growth, an industry pricing model, optimal dispatch availability, in-house training, and a controlled premium customer experience on modernized aircraft. The company has over 100 aircraft in its owned and leased fleet which includes light, midsize, super-midsize, and large jets. As one of the nation's Citation operators, it has curated a versatile fleet of Citation CJ3/CJ3 plus, Citation Excel/XLS/XLS plus, Citation Encore/Encore plus, Citation Sovereign, and Citation X aircraft.
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.